Bank of America Corp DE increased its stake in 908 Devices Inc. (NASDAQ:MASS - Free Report) by 190.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 94,753 shares of the company's stock after acquiring an additional 62,179 shares during the quarter. Bank of America Corp DE owned approximately 0.27% of 908 Devices worth $208,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. Jane Street Group LLC lifted its position in shares of 908 Devices by 118.9% in the fourth quarter. Jane Street Group LLC now owns 113,890 shares of the company's stock valued at $251,000 after acquiring an additional 61,851 shares in the last quarter. Northern Trust Corp raised its stake in 908 Devices by 7.5% in the 4th quarter. Northern Trust Corp now owns 200,764 shares of the company's stock valued at $442,000 after purchasing an additional 14,087 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in 908 Devices by 32.2% in the 4th quarter. Hsbc Holdings PLC now owns 21,007 shares of the company's stock valued at $46,000 after purchasing an additional 5,112 shares in the last quarter. Stifel Financial Corp acquired a new stake in 908 Devices during the 4th quarter worth $52,000. Finally, Marshall Wace LLP acquired a new stake in 908 Devices during the 4th quarter worth $85,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.
908 Devices Trading Down 1.6%
NASDAQ:MASS traded down $0.12 during trading hours on Monday, hitting $7.19. The company had a trading volume of 999,507 shares, compared to its average volume of 1,023,492. 908 Devices Inc. has a 1 year low of $1.81 and a 1 year high of $7.60. The company has a market cap of $257.84 million, a P/E ratio of -4.06 and a beta of 0.29. The company has a 50-day moving average of $5.37 and a 200 day moving average of $3.71.
908 Devices (NASDAQ:MASS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. The business had revenue of $11.78 million during the quarter, compared to the consensus estimate of $11.90 million. 908 Devices had a negative net margin of 109.11% and a negative return on equity of 24.60%. On average, analysts forecast that 908 Devices Inc. will post -1.99 earnings per share for the current year.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of 908 Devices in a research note on Wednesday, June 11th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, 908 Devices currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.33.
Read Our Latest Analysis on 908 Devices
Insider Buying and Selling at 908 Devices
In other 908 Devices news, CFO Joseph H. Iv Griffith sold 6,940 shares of 908 Devices stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $7.08, for a total value of $49,135.20. Following the completion of the transaction, the chief financial officer now directly owns 102,930 shares of the company's stock, valued at $728,744.40. The trade was a 6.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Mark Spoto purchased 10,000 shares of 908 Devices stock in a transaction dated Wednesday, May 14th. The shares were acquired at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the transaction, the director now directly owns 62,971 shares of the company's stock, valued at approximately $270,145.59. This represents a 18.88% increase in their position. The disclosure for this purchase can be found here. 23.70% of the stock is owned by corporate insiders.
908 Devices Company Profile
(
Free Report)
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
See Also
Before you consider 908 Devices, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 908 Devices wasn't on the list.
While 908 Devices currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
